RARanit Aharonov

Ranit Aharonov

*This is an algorithmically generated author record based on publicly available information.

Ranit Aharonov has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Alina Weissmann-Brenner

    Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel

    1 shared publication
  • Avital Dov

    From Rosetta Genomics Ltd, Rehovot; Cancer Research Center, Sheba Medical Center, Tel-Hashomer; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Rosetta Genomics Inc, Jersey City, NJ; Departments of Cardiothoracic Surgery and Pathology, New York University School of Medicine; and the Molecular Pathology Laboratory, Columbia University Medical Center, New York, NY

    1 shared publication
  • Ayelet Chajut

    From Rosetta Genomics Ltd, Rehovot; Cancer Research Center, Sheba Medical Center, Tel-Hashomer; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Rosetta Genomics Inc, Jersey City, NJ; Departments of Cardiothoracic Surgery and Pathology, New York University School of Medicine; and the Molecular Pathology Laboratory, Columbia University Medical Center, New York, NY

    1 shared publication
  • Baruch Brenner

    Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4910000, Israel; Gray Faculty of Medical & Health Sciences, Tel-Aviv University, Ramat Aviv, Tel Aviv 6997800, Israel

    1 shared publication
  • Daisuke Nonaka

    From Rosetta Genomics Ltd, Rehovot; Cancer Research Center, Sheba Medical Center, Tel-Hashomer; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Rosetta Genomics Inc, Jersey City, NJ; Departments of Cardiothoracic Surgery and Pathology, New York University School of Medicine; and the Molecular Pathology Laboratory, Columbia University Medical Center, New York, NY

    1 shared publication
  • Dalia Cohen

    From Rosetta Genomics Ltd, Rehovot; Cancer Research Center, Sheba Medical Center, Tel-Hashomer; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Rosetta Genomics Inc, Jersey City, NJ; Departments of Cardiothoracic Surgery and Pathology, New York University School of Medicine; and the Molecular Pathology Laboratory, Columbia University Medical Center, New York, NY

    1 shared publication

Latest Publications

  • Open Access

    Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer

    by Ranit Aharonov, Alina Weissmann-Brenner, Michal Kushnir, Gila Lithwick Yanai, Hadas Gibori, Ofer Purim, Yulia Kundel, Sara Morgenstern, Marissa Halperin, Yaron Niv, et al.

    There is emerging evidence for the prognostic role of various microRNA (miRNA) molecules in colon cancer. The aim of this study was therefore to compare the miRNA profiles in the primary tumor of patients with recurrent and non-recurrent colon cancer. The study population included 110 patients, 51 (46%) with stage I and 59 (54%) with stage II disease, who underwent curative colectomies between 1995 and 2005 without adjuvant therapy and for whom reliable miRNA expression data were available. RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples. Initial profiling, using microarrays, was done in order to identify potential biomarkers of recurrence. The miRNA expression was later verified by quantitative real-time polymerase chain reaction (qRT-PCR). Findings were compared between patients who had a recurrence within 36 months of surgery (bad prognosis group, n=23, 21%) and those who did not (good prognosis group, n=87, 79%) in the entire group and within each stage. The results showed that in stage I, none of the 903 miRNAs tested showed differential expression between patients with good prognosis compared with those with poor prognosis. In contrast, in stage II, one miRNA, miR-29a, showed a clear differential expression between the groups (p=0.028). High expression of miR-29a was associated with a longer disease-free survival (DFS), on both univariate and multivariate analyses. Using miR-29a, the positive predictive value for non-recurrence was 94% (2 recurrences among 31 patients). The differential expression of miR-29a was verified by qRT-PCR, showing a similar impact of this miR on DFS. In conclusion, this study demonstrated a significant impact of miR-29a on the risk of recurrence in patients with stage II but not in patients with stage I colon cancer. Based on these results, a validation study is planned.


  • Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma

    by Danit Lebanony, Hila Benjamin, Shlomit Gilad, Meital Ezagouri, Avital Dov, Karin Ashkenazi, Nir Gefen, Shai Izraeli, Gideon Rechavi, Harvey Pass, et al.

    Purpose: Recent advances in treatment of lung cancer require greater accuracy in the subclassification of non–small-cell lung cancer (NSCLC). Targeted therapies which inhibit tumor angiogenesis pose higher risk for adverse response in cases of squamous cell carcinoma. Interobserver variability and the lack of specific, standardized assays limit the current abilities to adequately stratify patients for such treatments. In this study, we set out to identify specific microRNA biomarkers for the identification of squamous cell carcinoma, and to use such markers for the development of a standardized assay. Patients and Methods: High-throughput microarray was used to measure microRNA expression levels in 122 adenocarcinoma and squamous NSCLC samples. A quantitative real-time polymerase chain reaction (qRT-PCR) platform was used to verify findings in an independent set of 20 NSCLC formalin-fixed, paraffin-embedded (FFPE) samples, and to develop a diagnostic assay using an additional set of 27 NSCLC FFPE samples. The assay was validated using an independent blinded cohort consisting of 79 NSCLC FFPE samples. Results: We identified hsa-miR-205 as a highly specific marker for squamous cell lung carcinoma. A microRNA-based qRT-PCR assay that measures expression of hsa-miR-205 reached sensitivity of 96% and specificity of 90% in the identification of squamous cell lung carcinomas in an independent blinded validation set. Conclusion: Hsa-miR-205 is a highly accurate marker for lung cancer of squamous histology. The standardized diagnostic assay presented here can provide highly accurate subclassification of NSCLC patients.